NCT03801629View on ClinicalTrials.gov

Neuroimmune Effects of Opioid Administration

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

September 12, 2019

Primary Completion Date

March 10, 2021

Study Completion Date

March 10, 2021

Conditions
Drug Effect
Interventions
DRUG

High Morphine Dose

Subjects will receive an intramuscular morphine injection (0.07mg/kg) in the non-dominant deltoid muscle. Metoclopramide (10mg; oral) will be administered PRN to reduce nausea.

DRUG

Low Morphine Dose

Subjects will receive an intramuscular morphine injection (0.04mg/kg) in the non-dominant deltoid muscle. Metoclopramide (10mg; oral) will be administered PRN to reduce nausea.

Trial Locations (1)

06519

Cosgrove Lab, New Haven

All Listed Sponsors
lead

Yale University

OTHER

NCT03801629 - Neuroimmune Effects of Opioid Administration | Biotech Hunter | Biotech Hunter